UN virus therapy trial pauses hydroxychloroquine testing
Source: AP
By MARIA CHENG and JAMEY KEATEN
GENEVA (AP) — The World Health Organization said Monday that it will temporarily drop hydroxychloroquine — the anti-malarial drug U.S. President Trump says he is taking — from its global study into experimental COVID-19 treatments, saying that its experts need to review all available evidence to date.
In a press briefing, WHO director-general Tedros Adhanom Ghebreyesus said that in light of a paper published last week in the Lancet that showed people taking hydroxychloroquine were at higher risk of death and heart problems, there would be “a temporary pause” on the hydroxychloroquine arm of its global clinical trial.
“This concern relates to the use of hydroxychloroquine and chloroquine in COVID-19,” Tedros said, adding that the drugs are approved treatments for people with malaria or autoimmune diseases. Other treatments in the trial, including the experimental drug remdesivir and an HIV combination therapy, are still being tested.
Tedros said the executive group behind WHO’s global “Solidarity” trial met on Saturday and decided to conduct a comprehensive review of all available data on hydroxychloroquine and that its use in the trial would be suspended for now.
FILE - This Tuesday, April 7, 2020 file photo shows a bottle of hydroxychloroquine tablets in Texas City, Texas. The World Health Organization said Monday May 25, 2020, that it will temporarily drop hydroxychloroquine from its global study into experimental COVID-19 treatments because its experts need to review all available evidence. (AP Photo/David J. Phillip, File)
Read more: https://apnews.com/dbae854cec0e40e859639540d8e54aac
= new reply since forum marked as read
